

Special Issue

Emerging Trends in Chimeric Antigen Receptor (CAR)-Based Cellular Immunotherapies

Message from the Guest Editors

Adoptive cell therapy (ACT) is an advanced approach to cancer treatment in which a patient's immune cells can be removed, engineered, expanded ex vivo, and transferred back into the patient to boost the anti-tumor immune response. The chimeric antigen receptor T (CAR-T) cell is a form of ACT that has revolutionized treatment for hematological malignancies. However, the success of CAR-T therapy for the treatment of solid tumors remains limited due to (1) antigen heterogeneity in solid tumors, (2) T-cell exhaustion, (3) inability to infiltrate solid tumors, or (4) immunosuppressive tumor microenvironment (TME). We invite the submission of original articles and reviews discussing the emerging trends in CAR-based immunotherapies for solid and hematological malignancies, chimeric engulfment receptor (CER) technology, biomarkers for CAR-based therapies, dendritic cell (DC) and regulatory (Treg) T-cell-based immunotherapies, multiplexing CAR, and CAR-based combination therapies. In addition, novel modalities for in vivo CAR therapies (e.g., mRNA-lipid nanoparticles) or pre-clinical investigations are also welcome.

Guest Editors

Dr. Abhinava Mishra

Molecular, Cellular and Developmental Biology Department, University of California Santa Barbara, Santa Barbara, CA 93106, USA

Dr. Sandeep Kumar

Department of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA

Deadline for manuscript submissions

closed (31 March 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/141125

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).